SwedenSweden

Karolinska with successful IPO

12.06.2011

Stockholm – Swedish investor Karolinska Development AB outperformed its own expectations in its Initial Public Offering on the Nasdaq OMX Stockholm. The company sold 15.2 million shares at SEK40 during the offering, raising a grand total of SEK608m (EUR67.5m). That puts the value of the investment firm at SEK1.9bn (EUR211m). Originally, Karolinska had said it hoped to sell up to 11.4 million shares at SEK37-SEK42 to raise at least SEK479m (a53m). Prior to the offering, the company had estimated the value of its investment portfolio at SEK1.5bn (EUR166.6m). The fresh money will support the portfolio through early 2014. By then, Karolinska expects to see enough M&A, IPO and partnership activity to be cash-flow positive. The fund has a 50% stake on average in its 40 portfolio companies, which contain 12 clinical stage projects, six of them in Phase II. SEB Enskilda was lead manager for the offering. The first day of trading was April 15th.

SwedenSweden

12.03.2012

Gothenburg – Researchers at the Sahlgrenska Academy have discovered a previously unknown mechanism which helps intestinal bacteria to affect the formation of blood vessels. In a study of mice, the team led by Fredrik Bäckhed...

SwedenSweden

08.03.2012

Swiss Nestlé S.A. has extended its collaboration agreement with BioGaia AB. The world’s largest nutrition company is paying up to €50.8m for a perpetual licence to use BioGaia’s patented Lacto­bacillus reuteri in infant nutrition...

SwedenSweden

08.03.2012

Stockholm – Swedish drug delivery specialist Orexo AB has announced the intention to cut its headcount by 30% in order to reduce the company's burn rate. The personnel reduction by 35 people is expected to lower the costs by a...

SwedenSweden

07.03.2012

After a long period of negotiations, Sweden’s Orexo AB and Belgium’s Janssen Pharmaceutica have terminated their joint research programmes. “Unfortunately, we lack the funds to continue on our own to develop the OX-CLI and OX-ESI...

SwedenSweden

06.03.2012

Uppsala/Moscow – Vaccine adjuvant specialist Isconova AB is set to begin receiving royalties and product revenues from Russian partner VetBioChem. The veterinary medicine company has launched two new rabies vaccines for dogs and...

SwedenSweden

23.02.2012

Stockholm - Probiotics can help prevent diseases, Swedish researchers have found out. The results are in sharp contrast with all health claim judgements involving probiotics published by the EU's food watchdog EFSA up to now. The...

SwedenSweden

16.02.2012

Huddinge – Full stop for one of Sweden's most promising biotech companies. Karo Bio has terminated the trial of its late-stage cholesterol drug eprotirome and won't proceed with its plans to spin off its preclinical operations....

SwedenSweden

19.12.2011

Helsingborg/Exton – Swedish drug developer DuoCort Pharma AB has been purchased by US-based biopharmaceuticals maker ViroPharma Inc. ViroPharma paid around €25m up front, but DuoCort’s former owners could end up receiving €97m...

SwedenSweden

15.12.2011

Stockholm/Cologne – Researchers at the Swedish Karolinska Institute and the University of Cologne have identified a new protein-based defense mechanism against cancer (Struct. & Molec. Biology, doi: 10.1038/10.1038/nsmb.2188)....

SwedenSweden

15.12.2011

Craigavon/Uppsala – Irish Almac Discovery, a member of the Almac Group, will begin cooperating with Uppsala-based Beactica AB to develop new cancer drug candidates. In late November, the companies announced that Beactica’s Sprint...

Displaying results 1 to 10 out of 182

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-sweden/article/karolinska-with-successful-ipo.html

Events

All Events

Stock list

All quotes

TOP

  • PHARMING (NL)0.48 EUR11.63%
  • MDX HEALTH (B)3.80 EUR10.79%
  • NEUROVIVE PHARMACEUTICAL AB (S)70.00 SEK8.53%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.46 EUR-10.26%

TOP

  • WILEX (D)2.82 EUR243.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)70.00 SEK44.3%
  • Allergy Therapeutics (UK)20.00 GBP34.4%

FLOP

  • HYBRIGENICS (F)1.72 EUR-28.0%
  • PROSENSA (NL)9.67 USD-23.4%
  • PROTHENA PLC (IE)17.79 USD-21.1%

TOP

  • SANTHERA (CH)59.90 CHF2836.3%
  • GW PHARMACEUTICALS (UK)431.00 GBP656.1%
  • PAION (D)2.42 EUR272.3%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.7%
  • CYTOS (CH)0.27 CHF-92.0%
  • PROSENSA (NL)9.67 USD-70.9%

No liability assumed, Date: 31.07.2014


Current issue

All issues

Product of the week

Products